Status:
UNKNOWN
Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation
Lead Sponsor:
University of Vermont
Conditions:
Opioid-use Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Despite the demonstrated effectiveness of agonist treatment for opioid dependence and alarming recent increases in overdose deaths, waiting lists for treatment persist. In a Behavioral \& Integrative ...
Detailed Description
Despite the demonstrated effectiveness of agonist treatment for opioid dependence and alarming recent increases in overdose deaths, waiting lists for treatment persist. Opioid-dependent individuals ca...
Eligibility Criteria
Inclusion
- For inclusion, participants must be \>=18 years old, in good health, meet DSM-V criteria for opioid use disorder, provide an opioid-positive urine and be currently waitlisted with a community opioid treatment clinic or provider.
Exclusion
- Those with a significant psychiatric or medical illness that may interfere with consent or participation will be excluded, as will those who are pregnant or nursing. Those dependent on sedative-hypnotics will be excluded, due to the medical risks and notably low success rates with sedative-dependent opioid abusers (Stitzer \& Chutuape, 1999).
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03420313
Start Date
March 1 2018
End Date
July 1 2021
Last Update
May 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vermont
Burlington, Vermont, United States, 05401